


# LOCF Interval MMRM Approach to Missing Data


PSI Journal Club  
Aug. 1, 2013

Scott Andersen


# Example: Protocol-Specified Visits




# Example: All Visits




# Example: Interval LOCF - MMRM




# Example: Interval LOCF - MMRM




# Example: All Visits




# Example: Per Protocol Visits - MMRM




# Example: Per Protocol Visits - MMRM




# Example: All Visits




# Example: Hybrid - MMRM




# Example: Hybrid - MMRM




# Example: All Visits



# Example: LOCF




# Example: LOCF



Observations: n=200


n=195

# Example: Summary



Intrvl LOCF-MMRM	n=200	n=195	n=160
Per Protocol-MMRM	n=200	n=175	n=150
Hybrid-MMRM	n=200	n=185	n=155
LOCF:	n=200	NA	n=195

# Figure 1 - Assumed Trajectories



# Sim Parm – Data Collection & Missingness

Schedule of Events									
		Baseline	<-- Post-baseline -->						
Visit		2	3	4	5	6	7	8	
Schedule A		X	X		X				X
Schedule B		X			X				X


## Amount missing

- 10%
- 50%

## Missingness Assumption

- MCAR
- MAR
- MNAR – Schedule A
- MNR2 – Schedule B

**Figure 2 - Percent Missing Data Patterns across Trajectories**



# Type I Error Rates (50% Missing)

Missingness Assumption	Trajectory	PP Visits MMRM	Hybrid MMRM	Interval LOCF MMRM	Benchmark LOCF
MCAR	1	4.84	4.68	5.16	5.02
	2	4.74	4.86	4.86	4.40
	4	5.04	6.54*	9.64*	23.8*
	5	5.04	5.28	5.32	8.12*
MAR	1	4.80	4.70	4.92	4.74
	2	5.08	4.96	5.30	5.10
	4	5.08	5.16	6.56*	32.6*
	5	5.34	5.30	6.02*	15.4*
MNAR	1	5.06	5.34	5.26	4.74
	2	4.80	5.00	5.16	5.22
	4	5.30	5.82	7.10*	29.1*
	5	4.98	5.20	5.18	12.5*
MNR2	1	4.96	5.18	5.12	5.04
	2	4.60	4.84	4.84	4.92
	4	4.94	4.68	6.18*	18.1*
	5	4.68	4.84	5.14	8.74*



denotes significance compared to 0.05,  $p < 0.05$ .

\* denotes McNemar's Test comparing to Per Protocol MMRM,  $p < 0.05$ .

# Type I Error Rates (10% Missing)

Missingness Assumption	Trajectory	PP Visits MMRM	Hybrid MMRM	Interval LOCF MMRM	Benchmark LOCF
MCAR	1	4.48	4.50	4.80	4.78
	2	5.44	5.46	5.36	5.28
	4	5.46	5.30	5.32	5.68
	5	5.12	5.06	4.92	5.00
	MAR	1	4.98	4.94	4.92
MAR	2	5.26	5.18	5.12	5.44
	4	5.34	5.36	5.32	7.70*
	5	5.08	5.20	5.14	6.12*
	MNAR	1	5.08	5.12	5.04
MNAR	2	5.02	5.22	5.16	5.08
	4	4.74	5.04	5.00	6.80*
	5	5.04	5.10	5.30	6.82*
	MNR2	1	5.60	5.38	5.30
MNR2	2	5.36	5.26	5.26	5.16
	4	5.00	4.88	4.78	5.70*
	5	5.28	5.20	5.22	5.16



denotes significance compared to 0.05,  $p < 0.05$ .

\* denotes McNemar's Test comparing to Per Protocol MMRM,  $p < 0.05$ .

# Bias Assessment (50%)

Missingness Assumption	Trajectory	PP Visits MMRM	Hybrid MMRM	Interval LOCF MMRM	Benchmark LOCF
MCAR	1	0.02	0.03	0.06	0.05
	2	-0.05	-0.07	-0.05	-0.03
	3	<b>-0.16</b>	<b>-0.29</b>	<b>-0.65</b>	<b>-1.17</b>
	4	0.05	<b>1.51</b>	<b>2.32</b>	<b>3.94</b>
	5	0.01	<b>0.44</b>	<b>0.82</b>	<b>1.83</b>
MAR	1	-0.10	-0.11	-0.10	-0.08
	2	-0.03	-0.03	-0.03	-0.05
	3	-0.06	0.03	<b>-0.18</b>	<b>-0.87</b>
	4	-0.02	<b>0.78</b>	<b>1.62</b>	<b>4.47</b>
	5	-0.01	<b>0.39</b>	<b>0.96</b>	<b>2.86</b>

Note:  favors active  
 favors placebo

# Bias Assessment (50%)

Missingness Assumption	Trajectory	PP Visits MMRM	Hybrid MMRM	Interval LOCF MMRM	Benchmark LOCF
MNAR	1	0.01	0.02	0.01	-0.02
	2	0.02	0.05	0.05	0.04
	3	<b>-0.65</b>	<b>-0.30</b>	<b>-0.29</b>	<b>-0.57</b>
	4	<b>-0.24</b>	<b>0.80</b>	<b>1.68</b>	<b>4.40</b>
	5	-0.06	<b>0.25</b>	<b>0.73</b>	<b>2.59</b>
MNR2	1	-0.07	-0.06	-0.04	-0.01
	2	0.08	0.06	0.03	-0.01
	3	<b>-0.56</b>	<b>-0.30</b>	<b>-0.29</b>	<b>-0.46</b>
	4	<b>-0.25</b>	<b>0.60</b>	<b>1.34</b>	<b>3.65</b>
	5	-0.09	<b>0.21</b>	<b>0.61</b>	<b>2.15</b>

Note:  favors active  
 favors placebo

# Bias Assessment (10%)

Missingness Assumption	Trajectory	PP Visits MMRM	Hybrid MMRM	Interval LOCF MMRM	Benchmark LOCF
MCAR	1	<b>-0.11</b>	<b>-0.11</b>	<b>-0.11</b>	<b>-0.11</b>
	2	0.03	0.04	0.04	0.05
	3	0.08	0.05	-0.03	<b>-0.16</b>
	4	-0.01	<b>0.19</b>	<b>0.33</b>	<b>0.78</b>
	5	0.01	0.07	<b>0.12</b>	<b>0.35</b>
MAR	1	0.01	0.00	0.00	0.00
	2	0.05	0.05	0.05	0.04
	3	-0.10	-0.03	<b>0.12</b>	<b>0.60</b>
	4	0.05	<b>0.16</b>	<b>0.39</b>	<b>1.71</b>
	5	-0.01	0.09	<b>0.27</b>	<b>1.21</b>

Note:  favors active  
 favors placebo

# Bias Assessment (10%)

Missingness Assumption	Trajectory	PP Visits	Hybrid	Interval LOCF	Benchmark
		MMRM	MMRM	MMRM	LOCF
MNAR	1	-0.03	-0.02	-0.01	-0.01
	2	-0.02	-0.03	-0.03	-0.04
	3	<b>-0.95</b>	<b>-0.68</b>	<b>-0.40</b>	<b>0.19</b>
	4	<b>-0.46</b>	<b>-0.27</b>	<b>0.15</b>	<b>1.42</b>
	5	<b>-0.12</b>	-0.04	<b>0.16</b>	<b>1.03</b>
MNR2	1	0.03	0.03	0.04	0.04
	2	-0.01	-0.02	-0.02	-0.02
	3	<b>-0.74</b>	<b>-0.50</b>	<b>-0.26</b>	<b>0.19</b>
	4	<b>-0.37</b>	<b>-0.21</b>	<b>0.13</b>	<b>1.07</b>
	5	<b>-0.10</b>	-0.05	0.09	<b>0.68</b>

Note:  favors active  
 favors placebo

# SE of Estimates at Visit 8

## 50% Missing

Missing Data Model	Interval			
	PP Visits	Hybrid	LOCF	Benchmark
MCAR	4.81	4.34	3.98	3.15
MAR	5.25	4.89	4.43	2.99
MNAR	4.76	4.52	4.29	3.13
MNR2	4.85	4.64	4.45	3.51

## 10% Missing

Missing Data Model	Interval			
	PP Visits	Hybrid	LOCF	Benchmark
MCAR	3.66	3.62	3.58	3.44
MAR	3.70	3.68	3.66	3.57
MNAR	3.55	3.55	3.55	3.48
MNR2	3.59	3.60	3.60	3.56

# Conclusions

- Per Protocol MMARM was superior
- LOCF Interval MMARM led to biases
- When writing phase 3/4 protocols, use Per Protocol Visits MMARM

# Acknowledgements

- Brian Millen
- Lingling (Jennifer) Xie
- Fangyi Zhao
- Craig Mallinckrodt

# References

- National Research Council (2010). The Prevention and Treatment of Missing Data in Clinical Trials. Panel on Handling Missing Data in Clinical Trials. Committee on National Statistics, Division of behavioral and Social Sciences and Education. Washington DC. The National Academies Press.
- Mallickrodt C, Kaiser C, Watkin J, Detke M, Molenberghs G, and Carroll R. “Type I error rates from likelihood-based repeated measures and analyses of incomplete longitudinal data.” *Pharmaceut. Statist.* 2004; 3: 171–186.
- Mallinckrodt, Craig H. , Clark, W. Scott and David, Stacy R.(2001) 'Accounting for Dropout Bias Using Mixed-Effects Models', *J Biopharm Stat*, 11: 1, 9 — 21.
- Lane P. Handling drop-out in longitudinal clinical trials: a comparison of the LOCF and MMRM approaches. *Pharmaceut. Statist.* 2008; 7: 93–106.
- Mallinckrodt C., Kaiser C., Watkin J., Molenberghs G., and Carroll R. The effect of correlation structure on treatment contrasts estimated from incomplete clinical trial data with likelihood-based repeated measures compared with last observation carried forward ANOVA. *Clinical Trials* 2004; 1: 477-489.

# References (cont.)

- Gueorguieva, R., & Krystal, J. H. (2004). Move over ANOVA: Progress in analyzing repeated-measures data and its reflection in papers published in the archives of general psychiatry. *Archives of General Psychiatry*, 61(3), 310-317.
- Siddiqui O, Hung J, O'Neill R: MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets. *J Biopharm Stat* 2009; 19:227–246.
- Fisher LD, Dixon DO, et al. Intention-to-Treat in clinical trials, in KE Peace (Ed.), *Statistical Issues in Drug Research and Development*. Marcel Dekker, 1990.
- Molenberghs G, Thijs H, Jansen I, et al. Analyzing incomplete longitudinal clinical trial data. *Biostatistics*. 2004;5:445–464.
- Shao J, Zhong B. Last observation carry-forward and last observation analysis. *Stat Med*. 2003;22: 2429–2441.
- Mallinckrodt C., Lane P., Schnell D., Peng Y., and Mancuso J. Recommendations for the Primary Analysis of Continuous Endpoints in Longitudinal Clinical Trials. *Drug Information Journal* 2008; 42: 303-19.
- European Medicines Agency (EMA) Guideline on Missing Data in Confirmatory Clinical Trials released April 2009 (CPMP/EWP/1776/99 Rev. 1 Corr).

# **BACK-UP SLIDES**

# Type I Error Rates (30% Missing)

Missingness Assumption	Trajectory	PP Visits MMRM	Hybrid MMRM	Interval LOCF MMRM	Benchmark LOCF	
MCAR	1	4.86	4.76	4.76	4.68	
	2	4.48	4.52	4.78	4.28	
	4	4.88	5.14	5.74*	10.5*	
	5	5.66	5.30	5.14*	5.92	
	MAR	1	4.84	4.58	4.50	4.64
MAR	2	4.88	4.90	5.34	4.90	
	4	4.76	5.24	6.50*	11.7*	
	5	4.66	5.04	5.54*	6.56*	
	MNAR	1	4.76	4.96	5.10	5.18
		2	4.68	4.82	4.88	4.96
4		5.30	5.04	5.54	17.5*	
5		4.80	4.42	4.76	9.48*	
MNR2		1	4.82	4.98	4.98	5.08
	2	4.50	4.58	4.62	4.64	
	4	5.10	4.78	5.58	16.4*	
	5	4.66	4.54	4.84	8.60*	



denotes significance compared to 0.05,  $p < 0.05$ .

\* denotes McNemar's Test comparing to Per Protocol MMRM,  $p < 0.05$ .

# SE of Estimates at Visit 8

30% Missing

Missing Data Model	Interval			
	PP Visits	Hybrid	LOCF	Benchmark
MCAR	4.11	3.92	3.76	3.31
MAR	4.18	3.95	3.72	3.30
MNAR	3.99	3.92	3.86	3.34
MNR2	4.01	3.93	3.86	3.34

# Bias Assessment (30%)

Missingness Assumption	Trajectory	PP Visits MMRM	Hybrid MMRM	Interval LOCF MMRM	Benchmark LOCF
MCAR	1	-0.00	-0.00	0.03	0.03
	2	0.01	-0.01	-0.01	-0.01
	3	<b>-0.13</b>	<b>-0.20</b>	<b>-0.34</b>	<b>-0.76</b>
	4	0.02	<b>0.72</b>	<b>1.26</b>	<b>2.38</b>
	5	0.02	<b>0.22</b>	<b>0.43</b>	<b>1.11</b>
MAR	1	-0.03	-0.00	0.02	0.01
	2	<b>0.12</b>	<b>0.12</b>	0.08	0.07
	3	0.03	-0.06	<b>-0.30</b>	<b>-0.66</b>
	4	-0.01	<b>0.81</b>	<b>1.40</b>	<b>2.53</b>
	5	0.03	<b>0.28</b>	<b>0.53</b>	<b>1.22</b>


Note:  favors active  
 favors placebo

# Bias Assessment (30%)


Missingness Assumption	Trajectory	PP Visits MMRM	Hybrid MMRM	Interval LOCF MMRM	Benchmark LOCF
MNAR	1	-0.02	-0.02	0.01	-0.02
	2	0.04	0.04	0.05	0.04
	3	<b>-1.23</b>	<b>-0.74</b>	<b>-0.46</b>	<b>-0.57</b>
	4	<b>-0.66</b>	-0.03	<b>0.69</b>	<b>3.28</b>
	5	<b>-0.34</b>	<b>-0.13</b>	0.09	<b>2.19</b>
MNR2	1	-0.06	-0.06	-0.03	-0.01
	2	-0.01	-0.02	-0.04	-0.01
	3	<b>-1.08</b>	<b>-0.63</b>	<b>-0.39</b>	-0.01
	4	<b>-0.52</b>	0.09	<b>0.80</b>	<b>3.17</b>
	5	<b>-0.29</b>	-0.06	<b>0.17</b>	<b>1.96</b>

Note:  favors active  
 favors placebo

# Simulation Parameters




# Simulation Parameters




# Missing Data Patterns


## MCAR - 50%




## MAR - 50%



## MNAR - 50%



## MNR2 - 50%



# Sim Parameters – Error (Co)variance

<b>300</b>	330	310	280	250	230	210
330	<b>400</b>	360	320	290	260	240
310	360	<b>410</b>	360	320	290	260
280	320	360	<b>420</b>	360	320	290
250	290	320	360	<b>430</b>	360	320
230	260	290	320	360	<b>440</b>	360
210	240	260	290	320	360	<b>450</b>

Mallinckrodt and Kaiser (2004). “Type I error rates from likelihood-based repeated measures analyses of incomplete longitudinal data.” *Pharmaceut. Statist.* 2004; 3: 171-186.

# Sim Parameters – Correlation Matrix

Visit	1	2	3	4	5	6	7
1	1.000						
2	0.953	1.000					
3	0.884	0.889	1.000				
4	0.789	0.781	0.868	1.000			
5	0.696	0.699	0.762	0.847	1.000		
6	0.633	0.620	0.683	0.744	0.828	1.000	
7	0.572	0.566	0.605	0.667	0.727	0.809	1.000
Variance	300	400	410	420	430	440	450

# Sim Parameters – Computing Details

- PC-SAS 9.1+ needed for RANDGEN function to simulate multivariate normal distribution
- 5,000 simulations of each missingness model (4), missingness amount (2), trajectory (5), and (co)variance structure (3) resulted in 600,000 total simulations

# Missingness Logistics – MCAR

- Scale results simulated for visits 2-8
- Early dropout visit assigned to each patient  $\sim \text{UNIF}(4,8)$
- First  $x\%$  (10 or 50) were considered early DC'ers
- Scale results kept for visits 2,3,5,8 and endpt.

# Missingness Logistics – MAR

- Scale results simulated for visits 2-8
- Each pt's worst score used to create distribution and threshold
- Pt's score at V3 compared to threshold and probability of being missing at V4 ( $p_4$ ) using UNIF(0,1) and compared to a limit; similarly,  $p_5$  computed.
- Pt's score at V5 compared to threshold and probabilities  $p_6$ ,  $p_7$  and  $p_8$  computed.
- Scale results kept for visits 2,3,5,8 and endpt.

# Missingness Logistics – MNAR/MNR2

- Scale results simulated for visits 2-8
- Each pt's worst score used to create distribution and threshold
- Each visit assigned a probability of being missing UNIF(0,1)
- Scale results kept for visits 2,3,5,8 and endpt for MNAR; 2, 5, 8, and endpoint for MNR2.